Takeda recalls Natpara but warns patients not to abruptly stop treatment

Takedaís been looking for a buyer for Natpara to provide some debt relief, but it has just run into some complicating circumstances. It is having to recall the drug from the market, a move it says may be very challenging for patients. Takeda today announced it was voluntarily recalling all doses of the injected drug for hypoparathyroidism in the U.S. because there was a chance of small rubber particles shedding into the injectors. But the Japanese drugmaker was adamant that patients mustnít stop the treatment abruptly because of the danger of a sudden drop in blood calcium levels. Instead, patients must have their doctor replace the drug with supplements and carefully monitor their calcium levels with blood tests.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001148 seconds